MedTrace Logo

Spanish Series of Patients Treated With the Radionuclide Lutetium177

NCT04949282 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2022-12-23

No results posted yet for this study

Summary

This study aims to pool the clinical experience of Spanish centers treating patients with 177Lu-DOTATATE to evaluate the efficacy, tolerance, and safety of the drug in routine clinical practice and to learn about the profiles of patients and tumors treated and the results in each type of patient and tumor.

Conditions

  • Neuroendocrine Tumors
  • Intestinal Neoplasms
  • Pancreatic Neoplasms
  • Stomach Neoplasms
  • Neuroectodermal Tumors
  • Neoplasms, Germ Cell and Embryonal
  • Neoplasms by Histologic Type
  • Neoplasms
  • Neoplasms, Nerve Tissue
  • Gastrointestinal Neoplasms
  • Digestive System Neoplasms
  • Neoplasms by Site
  • Endocrine Gland Neoplasms
  • Digestive System Diseases
  • Gastrointestinal Disease
  • Intestinal Diseases
  • Pancreatic Disease
  • Endocrine System Diseases

Interventions

DRUG

Lutetium [177Lu] oxodotreotide/dotatate

Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)

DEVICE

Lutetium [177Lu] oxodotreotide/dotatate

Radiopharmaceutical solution for infusion (7.4 GBq of Lutathera per 30 ml vial)

Sponsors & Collaborators

  • Sociedad Española de Medicina Nuclear e Imagen Molecular

    lead OTHER

Principal Investigators

  • Mercedes Dr Mitjavila Casanovas, MD-PhD · Sociedad Española de Medicina Nuclear e Imagen Molecular (SEMNIM)

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-10
Primary Completion
2034-12-31
Completion
2035-12-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04949282 on ClinicalTrials.gov